| Theme | Recent advance in the treatment of IBD based on the pathogenesis | |
|---|---|---|
| Title | S1P receptor agonist | |
| Publish Date | 2018/05 | |
| Author | Hideki Iijima | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Shinichiro Shinzaki | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Takahiro Inoue | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Shouichiro Kawai | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Toshio Yamaguchi | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Shuko Iwatani | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Takeo Yoshihara | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| Author | Tetsuo Takehara | Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine |
| [ Summary ] | The concentration gradient of sphingosine-1-phosphate (S1P) controls egress of lymphocytes expressing the S1P receptor from the secondary lymph nodes. S1P receptor agonists inhibit intestinal inflammation by inhibiting lymphocyte mobilization from intestinal lymph nodes to the intestinal lamina propria. A number of S1P receptor agonists have been developed and are expected to be new therapeutic agents for inflammatory bowel disease. | |